

Table SI. Multivariate logistic regression to assess the association of serum LDH^a with lymph node metastasis in FIGO stage subgroups.

	Q1	Q2	Q3	Q4	Trend	
FIGO stage ^b	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
IB	n=117	n=109	n=105	n=96		
Model 1	1 (Ref)	1.32 (0.55-3.20)	1.92 (0.83-4.45)	1.68 (0.70-4.01)	1.21 (0.93-1.57)	0.161
Model 2	1 (Ref)	1.44 (0.59-3.50)	2.21 (0.94-5.22)	1.87 (0.77-4.53)	1.25 (0.96-1.63)	0.101
Model 3	1 (Ref)	1.43 (0.58-3.52)	2.42 (1.01-5.78)	1.88 (0.77-4.59)	1.26 (0.96-1.65)	0.092
Model 4	1 (Ref)	1.38 (0.56-3.41)	2.56 (1.06-6.16)	1.82 (0.74-4.47)	1.26 (0.96-1.65)	0.094
Model 5	1 (Ref)	1.4 (0.56-3.51)	2.53 (1.04-6.15)	1.94 (0.78-4.84)	1.28 (0.97-1.69)	0.075
Model 6	1 (Ref)	1.69 (0.65-4.39)	2.94 (1.14-7.55)	1.73 (0.67-4.48)	1.22 (0.93-1.62)	0.157
IIA	(n=30)	(n=36)	(n=42)	(n=51)		
Model 1	1 (Ref)	2.57 (0.62-10.73)	1.80 (0.43-7.62)	6.83 (1.83-25.44)	1.80 (1.24-2.61)	0.002
Model 2	1 (Ref)	5.34 (1.1-25.99)	3.23 (0.68-15.27)	11.57 (2.72-49.26)	1.92 (1.31-2.81)	0.001
Model 3	1 (Ref)	5.48 (1.12-26.91)	3.34 (0.70-16.00)	11.75 (2.75-50.22)	1.92 (1.31-2.81)	0.001
Model 4	1 (Ref)	5.03 (0.97-26.14)	3.04 (0.59-15.58)	11.04 (2.42-50.34)	1.90 (1.27-2.83)	0.002
Model 5	1 (Ref)	9.35 (1.35-64.74)	5.39 (0.79-36.85)	16.46 (2.76-98.31)	1.94 (1.27-2.98)	0.002

Model 6	1 (Ref)	15.92 (2.00- 127.01)	3.60 (0.48- 26.89)	17.07 (2.62- 111.23)	1.83 (1.18- 2.84)	0.007
---------	---------	-------------------------	-----------------------	-------------------------	----------------------	-------

^aFirst, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. Ca125, cancer antigen 125; FIGO, the International Federation of Gynecology and Obstetrics; LDH, serum lactate dehydrogenase; OR, odds ratio; Ref, reference.

Table SII. Multivariate logistic regression to assess the association of serum LDH^a with lymph node metastasis in different age subgroups.

	Q1	Q2	Q3	Q4	Trend	
Age ^b , years	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
<45	n=80	n=50	n=40	n=50		
Model 1	1 (Ref)	1.08 (0.41- 2.86)	2.15 (0.85- 5.43)	1.24 (0.48- 3.21)	1.14 (0.86- 1.53)	0.366
Model 2	1 (Ref)	1.29 (0.47- 3.53)	2.12 (0.81- 5.57)	1.02 (0.38- 2.76)	1.07 (0.79- 1.44)	0.651
Model 3	1 (Ref)	1.28 (0.47- 3.52)	2.26 (0.85- 6.03)	1.04 (0.38- 2.81)	1.08 (0.80- 1.46)	0.624
Model 4	1 (Ref)	1.18 (0.42- 3.31)	2.17 (0.79- 6.00)	0.85 (0.3-2.37)	1.02 (0.75- 1.39)	0.910
Model 5	1 (Ref)	1.32 (0.45- 3.84)	2.27 (0.8- 6.41)	0.95 (0.33- 2.75)	1.05 (0.76- 1.44)	0.766
Model 6	1 (Ref)	1.89 (0.59- 6.02)	2.1 (0.66- 6.71)	0.54 (0.16- 1.76)	0.89 (0.63- 1.25)	0.507
≥45	n=67	n=95	n=107	n=97		
Model 1	1 (Ref)	9.54 (1.21- 75.22)	8.34 (1.06- 65.63)	24.17 (3.19- 183.01)	2.01 (1.44- 2.80)	<0.001
Model 2	1 (Ref)	9.21 (1.16- 72.82)	8.16 (1.03- 64.41)	22.8 (3.00- 173.17)	1.98 (1.42- 2.76)	<0.001
Model 3	1 (Ref)	1 (Ref)	10.43 (1.31- 83.15)	8.71 (1.10- 69.23)	23.69 (3.10- 181.22)	<0.001
Model 4	1 (Ref)	10.23 (1.28- 81.76)	8.48 (1.06- 67.6)	24.27 (3.16- 186.2)	1.98 (1.41- 2.78)	<0.001
Model 5	1 (Ref)	12.73 (1.39- 118.1)	10.5 (1.14- 97.8)	28.62 (3.23- 250.1)	1.98 (1.40- 2.82)	<0.001

		116.82)	96.96)	253.29)	2.81)	
Model 6	1 (Ref)	15.65 (1.69- 145.13)	10.07 (1.07- 94.28)	29.68 (3.33- 264.52)	1.94 (1.35- 2.78)	<0.001

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. Ca125, cancer antigen 125; LDH, serum lactate dehydrogenase; OR, odds ratio; Ref, reference.

Table SIII. Multivariable logistic regression to assess the association of serum LDH^a with lymph node metastasis in different Ca125 subgroups.

Ca125 ^b , <35 ng/ml	Q1 (n=136)	Q2 (n=135)	Q3 (n=133)	Q4 (n=136)	Trend	
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
Model 1	1 (Ref)	1.53 (0.68- 3.43)	1.78 (0.81- 3.93)	3.50 (1.68- 7.28)	1.50 (1.20- 1.89)	<0.001
Model 2	1 (Ref)	2.83 (1.15- 6.96)	2.73 (1.11- 6.74)	4.04 (1.76- 9.27)	1.48 (1.16- 1.88)	<0.001
Model 3	1 (Ref)	1.77 (0.77- 4.03)	2.08 (0.92- 4.7)	3.85 (1.81- 8.22)	1.53 (1.22- 1.93)	<0.001
Model 4	1 (Ref)	1.82 (0.80- 4.19)	2.23 (0.98- 5.08)	3.95 (1.84- 8.48)	1.54 (1.22- 1.95)	<0.001
Model 5	1 (Ref)	1.81 (0.79- 4.17)	2.34 (1.02- 5.35)	3.85 (1.79- 8.3)	1.53 (1.21- 1.93)	<0.001
Model 6	1 (Ref)	2.15 (0.90- 5.13)	2.66 (1.12- 6.34)	4.22 (1.88- 9.47)	1.55 (1.22- 1.96)	<0.001
Model 7	1 (Ref)	2.83 (1.15- 6.96)	2.73 (1.11- 6.74)	4.04 (1.76- 9.27)	1.48 (1.16- 1.88)	<0.001

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. Ca125, cancer antigen 125; LDH, serum lactate dehydrogenase; OR, odds ratio; Ref, reference.

Table SIV. Multivariable logistic regression to assess the association of serum LDH with lymph node metastasis in squamous cell carcinoma subgroup.

Squamous cell carcinoma ^b	Q1, n=117	Q2, n=110	Q3, n=117	Q4, n=122	Trend	
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
Model 1	1 (Ref)	1.96 (0.85-4.48)	2.34 (1.05-5.22)	3.49 (1.62-7.52)	1.46 (1.16-1.83)	0.001
Model 2	1 (Ref)	2.29 (0.99-5.31)	2.87 (1.26-6.5)	4.27 (1.95-9.38)	1.54 (1.23-1.94)	<0.001
Model 3	1 (Ref)	2.27 (0.97-5.28)	2.73 (1.2-6.22)	3.91 (1.77-8.65)	1.50 (1.19-1.89)	0.001
Model 4	1 (Ref)	2.28 (0.97-5.33)	2.88 (1.25-6.6)	3.97 (1.79-8.8)	1.51 (1.19-1.9)	0.001
Model 5	1 (Ref)	2.27 (0.97-5.35)	2.92 (1.26-6.77)	3.85 (1.72-8.63)	1.49 (1.18-1.89)	0.001
Model 6	1 (Ref)	2.52 (1.05-6.08)	3.07 (1.29-7.33)	3.99 (1.74-9.15)	1.49 (1.17-1.89)	0.001
Model 7	1 (Ref)	3.04 (1.22-7.57)	2.88 (1.16-7.17)	3.52 (1.49-8.32)	1.40 (1.09-1.79)	0.009

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. LDH, serum lactate dehydrogenase; OR, odds ratio; Ref, reference.

Table SV. Multivariable logistic regression to assess the association of serum LDH ^a with lymph node metastasis in different SCC-Ag subgroups.

	Q1	Q2	Q3	Q4	Trend	
SCC-Ag ^b , ng/ml	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
<1.5	n=76	n=68	n=84	n=62		
Model 1	1 (Ref)	0.93 (0.27- 3.18)	1.23 (0.41- 3.72)	2.8 (0.98- 7.96)	1.45 (1.01- 2.06)	0.042
Model 2	1 (Ref)	1.01 (0.29- 3.53)	1.41 (0.45- 4.41)	3.09 (1.07- 8.95)	1.50 (1.05- 2.13)	0.027
Model 3	1 (Ref)	1 (0.28- 3.61)	1.53 (0.47- 4.94)	3.05 (1.02- 9.14)	1.50 (1.04- 2.15)	0.029
Model 4	1 (Ref)	1.02 (0.28- 3.7)	1.64 (0.5- 5.41)	3.31 (1.09- 10.1)	1.54 (1.07- 2.23)	0.021
Model 5	1 (Ref)	1.08 (0.29- 4.04)	1.68 (0.49- 5.72)	3.44 (1.08- 10.88)	1.55 (1.07- 2.27)	0.022
Model 6	1 (Ref)	0.89 (0.22- 3.6)	1.71 (0.5- 5.84)	3.38 (1.06- 10.75)	1.58 (1.07- 2.32)	0.021
Model 7	1 (Ref)	1.30 (0.28- 6.04)	1.76 (0.48- 6.48)	2.12 (0.61- 7.36)	1.29 (0.87- 1.92)	0.213
≥1.5	n=71	n=77	n=63	n=85		
Model 1	1 (Ref)	2.21 (0.84- 5.79)	2.86 (1.08- 7.55)	3.39 (1.36- 8.47)	1.42 (1.09- 1.84)	0.008
Model 2	1 (Ref)	2.64 (0.99- 7.03)	3.58 (1.32- 9.73)	4.15 (1.62- 10.61)	1.49 (1.15- 1.94)	0.003
Model 3	1 (Ref)	2.77 (1.03- 7.45)	3.34 (1.22- 9.16)	3.80 (1.47- 9.82)	1.44 (1.1- 1.88)	0.008
Model 4	1 (Ref)	2.82 (1.04- 7.64)	3.43 (1.25- 9.41)	3.82 (1.48- 9.9)	1.44 (1.1- 1.88)	0.008

Model 5	1 (Ref)	2.79 (1.03-7.54)	3.32 (1.2-9.17)	3.77 (1.46-9.77)	1.43 (1.1-1.87)	0.009
Model 6	1 (Ref)	3.66 (1.24-10.77)	4.13 (1.37-12.43)	4.55 (1.61-12.87)	1.46 (1.11-1.93)	0.007
Model 7	1 (Ref)	4.26 (1.41-12.84)	3.47 (1.1-10.96)	4.36 (1.5-12.66)	1.41 (1.06-1.88)	0.019

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. LDH, serum lactate dehydrogenase; OR, odds ratio; SCC-Ag, squamous cell carcinoma antigen; Ref, reference.

Table SVI. Multivariable logistic regression to assess the association of serum LDH^a with lymph node metastasis in different LVSI subgroups.

	Q1	Q2	Q3	Q4	Trend	
LVSI ^b	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
Negative	n=99	n=110	n=99	n=80		
Model 1	1 (Ref)	2.30 (0.78- 6.79)	1.65 (0.52- 5.24)	3.00 (1- 9.02)	1.31 (0.95- 1.8)	0.102
Model 2	1 (Ref)	1.48 (0.5- 4.43)	2.27 (0.86- 6.02)	2.79 (1.12- 6.92)	1.40 (1.06- 1.86)	0.054
Model 3	1 (Ref)	2.67 (0.88- 8.11)	2.06 (0.62- 6.83)	3.46 (1.1- 10.95)	1.36 (0.98- 1.89)	0.070
Model 4	1 (Ref)	2.76 (0.9- 8.42)	2.19 (0.65- 7.3)	3.55 (1.12- 11.28)	1.37 (0.98- 1.91)	0.062
Model 5	1 (Ref)	2.76 (0.89- 8.52)	2.24 (0.67- 7.57)	3.33 (1.03- 10.71)	1.34 (0.96- 1.87)	0.083
Model 6	1 (Ref)	2.80 (0.88- 8.88)	2.33 (0.68- 8.03)	3.50 (1.06- 11.51)	1.36 (0.97- 1.91)	0.073
Model 7	1(Ref)	3.21 (0.97- 10.66)	2.41 (0.67- 8.68)	3.76 (1.09-12.97)	1.36 (0.96- 1.93)	0.080
Positive	n=48	n=35	n=48	n=67		
Model 1	1 (Ref)	2.60 (0.87- 7.77)	1.97 (0.60- 6.42)	3.63 (1.16- 11.29)	1.38 (1.00- 1.92)	0.018
Model 2	1 (Ref)	1.65 (0.54- 4.99)	2.56 (0.95- 6.9)	2.93 (1.17- 7.32)	1.41 (1.07- 1.87)	0.015
Model 3	1 (Ref)	1.83 (0.59- 5.68)	2.34 (0.85- 6.45)	2.59 (1.02- 6.63)	1.34 (1.01- 1.79)	0.046
Model 4	1 (Ref)	1.90 (0.60- 5.68)	2.55 (0.9- 6.45)	2.61 (1.00- 6.63)	1.34 (1.00- 1.79)	0.048

		6.02)	7.18)	6.8)	1.8)	
Model 5	1 (Ref)	1.70 (0.53- 5.46)	2.32 (0.82- 6.57)	2.39 (0.91- 6.27)	1.31 (0.98- 1.77)	0.071
Model 6	1 (Ref)	2.04 (0.58- 7.11)	3.10 (1.00- 9.64)	2.83 (0.99- 8.14)	1.37 (1.00- 1.88)	0.051
Model 7	1 (Ref)	2.05 (0.58- 7.24)	2.74 (0.84- 8.89)	2.96 (1.02- 8.6)	1.39 (1.00- 1.93)	0.047

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. LDH, serum lactate dehydrogenase; LVSI, lymph-vascular space invasion; OR, odds ratio; Ref, reference.

Table SVII. Multivariable logistic regression to assess the association of serum LDH with lymph node metastasis in different DSI subgroups.

	Q1	Q2	Q3	Q4	Trend	
DSI	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
<1/3	n=68	n=77	n=66	n=56		
Model 1	1 (Ref)	0.88 (0.17- 4.5)	1.40 (0.30- 6.50)	2.60 (0.62- 10.91)	1.44 (0.89- 2.33)	0.133
Model 2	1 (Ref)	1.16 (0.22- 6.15)	2.12 (0.42- 10.65)	3.67 (0.83- 16.26)	1.60 (0.99- 2.58)	0.055
Model 3	1 (Ref)	1.26 (0.23- 6.86)	2.43 (0.47- 12.44)	3.7 (0.82- 16.74)	1.59 (0.99- 2.56)	0.057
Model 4	1 (Ref)	1.41 (0.25- 7.97)	2.88 (0.53- 15.61)	4.43 (0.92- 21.35)	1.68 (1.03- 2.75)	0.038
Model 5	1 (Ref)	1.46 (0.25- 8.38)	3.22 (0.58- 17.86)	4.11 (0.84- 20.16)	1.64 (1.00- 2.67)	0.048
Model 6	1 (Ref)	1.37 (0.24- 7.79)	2.90 (0.53- 15.75)	3.63 (0.75- 17.56)	1.57 (0.97- 2.56)	0.068
Model 7	1 (Ref)	1.44 (0.24- 8.67)	3.00 (0.52- 17.23)	3.35 (0.65- 17.31)	1.52 (0.93- 2.51)	0.097
≥1/3- <2/3	n=48	n=47	n=42	n=65		
Model 1	1 (Ref)	2.14 (0.72- 6.36)	1.40 (0.43- 4.55)	2.48 (0.90- 6.87)	1.25 (0.93- 1.7)	0.142
Model 2	1 (Ref)	2.41 (0.80- 7.29)	1.60 (0.48- 5.31)	2.71 (0.97- 7.62)	1.28 (0.95- 1.73)	0.110
Model 3	1 (Ref)	2.31 (0.75- 7.39)	1.62 (0.48- 5.61)	2.50 (0.88- 6.77)	1.25 (0.92- 1.69)	0.155

		7.05)	5.41)	7.10)	1.70)	
Model 4	1 (Ref)	2.38 (0.78- 7.31)	1.75 (0.52- 5.91)	2.53 (0.89- 7.20)	1.25 (0.92- 1.70)	0.148
Model 5	1 (Ref)	2.37 (0.77- 7.36)	1.63 (0.48- 5.58)	2.52 (0.88- 7.23)	1.25 (0.92- 1.70)	0.159
Model 6	1 (Ref)	2.27 (0.72- 7.12)	1.65 (0.48- 5.65)	2.35 (0.81- 6.84)	1.23 (0.9- 1.69)	0.197
Model 7	1 (Ref)	2.31 (0.73- 7.29)	1.73 (0.50- 5.96)	2.22 (0.75- 6.52)	1.21 (0.88- 1.67)	0.240
$\geq 2/3$	n=31	n=21	n=39	n=26		
Model 1	1 (Ref)	2.70 (0.66- 11.1)	3.00 (0.86- 10.48)	5.79 (1.57- 21.29)	1.69 (1.14- 2.52)	0.009
Model 2	1 (Ref)	3.66 (0.84- 16.00)	4.28 (1.15- 15.96)	8.31 (2.09- 33.03)	1.88 (1.24- 2.85)	0.003
Model 3	1 (Ref)	4.48 (0.97- 20.71)	3.48 (0.89- 13.65)	7.36 (1.78- 30.47)	1.75 (1.15- 2.68)	0.010
Model 4	1 (Ref)	4.79 (0.98- 23.31)	3.58 (0.87- 14.68)	7.02 (1.63- 30.11)	1.72 (1.11- 2.65)	0.014
Model 5	1 (Ref)	4.21 (0.85- 20.89)	3.26 (0.77- 13.84)	7.10 (1.6- 31.42)	1.74 (1.11- 2.72)	0.016
Model 6	1 (Ref)	7.59 (1.16- 49.51)	5.45 (0.94- 31.59)	9.98 (1.65- 60.43)	1.78 (1.1- 2.89)	0.019
Model 7	1 (Ref)	9.39 (1.27- 69.27)	3.81 (0.62- 23.34)	7.36 (1.14- 47.57)	1.58 (0.95- 2.64)	0.077

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model

6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. DSI, deep stromal invasion; LDH, serum lactate dehydrogenase; OR, odds ratio; Ref, reference.

Table SVIII. Multivariable logistic regression to assess the association of serum LDH with lymph node metastasis in different tumor size subgroups.

	Q1	Q2	Q3	Q4	Trend	
Tumor size, cm	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	P-value
<2	n=59	n=55	n=59	n=53		
Model 1	1 (Ref)	1.08 (0.26- 4.54)	1.56 (0.42- 5.83)	3.6 (1.07- 12.11)	1.59 (1.07- 2.38)	0.023
Model 2	1 (Ref)	1.16 (0.27- 4.94)	1.72 (0.45- 6.67)	3.98 (1.14- 13.85)	1.64 (1.1- 2.47)	0.017
Model 3	1 (Ref)	1.24 (0.28- 5.46)	1.91 (0.48- 7.58)	4.13 (1.15- 14.9)	1.65 (1.1- 2.49)	0.016
Model 4	1 (Ref)	1.35 (0.3- 6.15)	2.01 (0.5- 8.09)	4.52 (1.21- 16.9)	1.69 (1.11- 2.56)	0.014
Model 5	1 (Ref)	1.32 (0.29- 6.08)	1.88 (0.46- 7.65)	4.54 (1.21- 17.01)	1.69 (1.11- 2.57)	0.014
Model 6	1 (Ref)	0.93 (0.18- 4.89)	1.88 (0.46- 7.75)	4.13 (1.09- 15.63)	1.71 (1.1- 2.64)	0.016
Model 7	1 (Ref)	0.84 (0.14- 5.1)	2.56 (0.58- 11.18)	3.6 (0.9- 14.42)	1.64 (1.05- 2.56)	0.029
≥2-<4	n=59	n=55	n=50	n=54		
Model 1	1 (Ref)	1.08 (0.35- 3.32)	1.86 (0.65- 5.31)	1.69 (0.59- 4.81)	1.23 (0.89- 1.7)	0.215
Model 2	1 (Ref)	1.24 (0.4- 3.87)	2.18 (0.74- 6.4)	1.87 (0.65- 5.44)	1.27 (0.91- 1.76)	0.160
Model 3	1 (Ref)	1.22 (0.39- 3.85)	2.07 (0.7- 6.15)	1.68 (0.57- 4.95)	1.22 (0.87- 1.7)	0.246
Model 4	1 (Ref)	1.24 (0.39- 3.85)	2.36 (0.78- 7.65)	1.78 (0.59- 5.44)	1.25 (0.89- 1.76)	0.197

		3.96)	7.18)	5.33)	1.75)	
Model 5	1 (Ref)	1.27 (0.4-4.1)	2.36 (0.77-7.22)	1.75 (0.58-5.29)	1.24 (0.88-1.74)	0.216
Model 6	1 (Ref)	1.88 (0.52-6.73)	3.18 (0.94-10.82)	2.33 (0.69-7.89)	1.31 (0.92-1.87)	0.136
Model 7	1 (Ref)	2.27 (0.61-8.47)	2.4 (0.67-8.63)	1.68 (0.47-6)	1.15 (0.79-1.68)	0.463
>4	n=29	n=35	n=38	n=40		
Model 1	1 (Ref)	4.67 (0.92-23.71)	3.05 (0.58-15.94)	7.27 (1.5-35.17)	1.58 (1.07-2.34)	0.019
Model 2	1 (Ref)	4.86 (0.94-25.18)	3.23 (0.59-17.62)	7.52 (1.53-36.99)	1.59 (1.08-2.35)	0.025
Model 3	1 (Ref)	5.02 (0.96-26.17)	3.17 (0.58-17.36)	7.27 (1.47-35.88)	1.57 (1.06-2.31)	0.028
Model 4	1 (Ref)	5.06 (0.97-26.43)	3.32 (0.6-18.3)	7.09 (1.43-35.1)	1.55 (1.05-2.29)	0.047
Model 5	1 (Ref)	5.24 (0.95-28.88)	3.29 (0.57-18.94)	6.69 (1.29-34.64)	1.51 (1-2.27)	0.016
Model 6	1 (Ref)	4.44 (0.79-24.81)	2.5 (0.41-15.14)	5.44 (1.02-28.96)	1.43 (0.94-2.18)	0.099
Model 7	1 (Ref)	6.33 (1.07-37.52)	1.93 (0.3-12.54)	5.85 (1.06-32.3)	1.38 (0.9-2.13)	0.142

^aThe first, second and third quartiles of LDH level (98.4-683.0 U/l) were 143.6, 167.9 and 208.1 U/l, divided into Q1, Q2, Q3 and Q4 group. ^bModel 1, no adjustment; Model 2, adjusted for age in analyses; Model 3, adjusted as for model 2, additionally adjusted for neoadjuvant chemotherapy; Model 4, adjusted as for model 3, additionally adjusted for squamous cell carcinoma antigen, cancer antigen 125; Model 5, adjusted as for model 4, additionally adjusted for surgical margin and parametrial involvement; Model 6, adjusted as for model 5, additionally adjusted for tumor size, lymph-vascular space invasion and deep stromal invasion. LDH, serum lactate dehydrogenase; OR, odds ratio;

Ref, reference.